Skip to contentN
Niagen Bioscience, Inc.
N
NAGENiagen Bioscience, Inc. Q4 2025 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$33.84M$33.84Mderived+16.2% vs Q4 2024 Net Income$4.13M$4.13Mderived−42.4% vs Q4 2024 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Niagen Bioscience, Inc. · CIK 1386570 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Gross Profitderived$21,704,000+19.3% Operating Incomederived$4,086,000−42.5% Operating Cash Flowderived$679,000−92.1% Margins · derivedGross margin64.1%+1.7 pt vs Q4 2024
Operating margin12.1%−12.3 pt vs Q4 2024
Net margin12.2%−12.4 pt vs Q4 2024
ended Dec 31, 2025 · filed Mar 4, 2026 · 63 d after period end